Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine
- 1 December 2004
- journal article
- Published by Elsevier BV in Journal of Gastrointestinal Surgery
- Vol. 8 (8), 1072-1078
- https://doi.org/10.1016/j.gassur.2004.09.054
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Usage of the NF‐κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancerInternational Journal of Cancer, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- C-JUN and CPP32 (CASPASE 3) in Human Pancreatic Cancer: Relation to Cell Proliferation and DeathPancreas, 2003
- Inhibition of nuclear factor κB chemosensitizes non–small cell lung cancer through cytochrome c release and caspase activationThe Journal of Thoracic and Cardiovascular Surgery, 2002
- Gemcitabine Alone or Combined with Cisplatin in Relapsed or Refractory Multiple MyelomaLeukemia & Lymphoma, 2002
- Chemosensitization of Pancreatic Cancer by Inhibition of the 26S ProteasomeJournal of Surgical Research, 2001
- 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancerJournal of Cellular Biochemistry, 2001
- The Pattern of CPP32/Caspase-3 Expression Reflects the Biological Behavior of the Human Pancreatic Duct Cell TumorsPancreas, 2000
- Human ICE/CED-3 Protease NomenclatureCell, 1996
- Action of 2',2'-difluorodeoxycytidine on DNA synthesis.1991